Breathe Well Live Well
Condition: Asthma
Interventions: Other: Denver Health Asthma Management Program; Other: Person of Support
Sponsors: Denver Health and Hospital Authority; University of Colorado, Denver
Enrolling by invitation – verified August 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Intervention: Drug: Busonid (budesonide 200mcg and 400mcg)
Sponsor: Ache Laboratorios Farmaceuticos S.A.
Not yet recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Conditions: Allergic Rhinitis; Rhinoconjunctivitis; Asthma
Intervention: Biological: Allergovac Poliplus
Sponsor: BIAL Industrial Farmacéutica S.A.
Not yet recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Intervention: Behavioral: Iggy and the Inhalers Asthma Education for Kids
Sponsor: Advocate Health Care
Recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Living near sites that extract natural gas by hydraulic fracturing, also known as fracking, may increase the risk of asthma up to four times, a US study said Monday. The findings, published in the Journal of the American Medical Association (JAMA) Internal Medicine, are based on research examining health records collected from 2005 to 2012 in the northeastern state of Pennsylvania. The researchers found more than 35,000 asthma patients aged from five to 90.
View full post on Health News Headlines – Yahoo News
Polymorphic Variants 279R and 668Q Augment Activity of Matrix Metalloproteinase-9 in Breath Condensates of Children with Asthma.
Arch Immunol Ther Exp (Warsz). 2016 Jul 9;
Authors: Grzela K, Zagórska W, Krejner A, Litwiniuk M, Zawadzka-Krajewska A, Kulus M, Grzela T
Abstract
Matrix metalloproteinase (MMP)-9 is involved in pathophysiology of asthma, mainly asthma-associated airway remodeling. Exhaled breath condensates (EBC) of asthmatics contain increased amounts of MMP-9 with activity higher, than in healthy controls. The increased activity of MMP-9 may originate from its excessive production and activation, but may also result from variations in MMP-9 structure, which are determined by single nucleotide polymorphisms (SNPs). In this pilot study we aimed to assess the possible influence of two functional MMP-9 polymorphisms, Q279R and R668Q, on enzymatic activity of MMP-9, measured in EBC of asthmatic children. The concentration and activity of MMP-9 were analyzed in EBC of 20 children with allergic asthma using specific standard ELISA and novel immunoenzymatic activity assay. The SNPs of MMP-9 were assessed using real-time PCR-based genotyping test. We have found that MMP-9 concentration in breath condensates of children with stable asthma was slightly higher in ELISA, than in the activity assay. Moreover, these results and activity-to-amount ratio have revealed some relationship with a presence of specific 279R and/or 668Q MMP-9 gene variants. Our observation suggests that at least in some patients MMP-9 hyperactivity may result from genetic predisposition, determined by polymorphic variants of MMP-9 gene. Moreover, it supports previous reports postulating significance of MMP-9 in pathogenesis of asthma. However, this issue still requires further studies.
PMID: 27395373 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):791-3
Authors: Liccardi G, Salzillo A, Calzetta L, Ora J, Cazzola M, Matera MG, Rogliani P
PMID: 27393788 [PubMed – in process]
View full post on pubmed: asthma
 |
Objective measurement of frequency and pattern of nocturnal cough in children with asthma exacerbation.
Ann Allergy Asthma Immunol. 2016 Jun 30;
Authors: Hirai K, Enseki M, Tabata H, Nukaga M, Matsuda S, Kato M, Furuya H, Mochizuki H
Abstract
BACKGROUND: Although a number of patients with asthma report experiencing persistent cough during sleep, it has not yet been objectively investigated.
OBJECTIVE: To classify cough severity and evaluate a characteristic pattern of cough frequency in children with asthma using an objective cough monitoring system.
METHODS: An objective cough monitoring system that specialized in children was used to measure cough frequency and nocturnal cough patterns. Coughs were recorded with microphone and accelerometer and analyzed using a customized software program. The number of nocturnal coughs and the pattern of cough frequency in 30-minute intervals were measured along with the severity of each asthma exacerbation, and the results were compared with children without asthma.
RESULTS: The total overnight cough count of 34 children with asthma was higher than that of 15 children without asthma (P < .001). The total overnight cough count in children with severe asthma exacerbation was higher than that in children with moderate asthma exacerbation (P < .05). The cough counts were significantly increased at the time of falling asleep and waking. This pattern was not observed in children without asthma. The total cough counts and cough patterns in children with asthma were not affected by sex, age, cause of asthma exacerbation, or therapy.
CONCLUSION: Our data indicate huge cough counts and characteristic nocturnal cough patterns in children with asthma. Objective and precise cough monitoring is useful for the management of childhood asthma.
PMID: 27372657 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
[Lipid derivative of benzylidene malononitrile AG490 attenuates airway inflammation of mice with neutrophilic asthma].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Jun;32(6):730-733
Authors: Zhang M, Nong G, Jiang M, Zhan W
Abstract
Objective To observe the effect of lipid derivative of benzylidene malononitrile AG490 on the airway inflammation in a mouse model of neutrophilic asthma (NA). Methods Fifty-four specific pathogen-free (SPF) female C57BL/6 mice were randomly divided into 3 groups: NA group, AG490-treated NA (NAAG) group, and normal control (NC) group, 18 mice in each group. The NA group and the NAAG group were sensitized by airway instillation of ovalbumin (OVA) and lipopolysaccharide (LPS) on day 0, 6 and 13. The NAAG group was injected with AG490 (500 ?g/mouse, i.p.) three times a week, from day 0 after the first sensitization, for 3 weeks. Mice were challenged on day 21, 22 for 1 hour/time with an aerosol of 10 g/L OVA. At 24 hours after the final challenge, bronchoalveolar lavage fluid (BALF) was collected. The total number and differential counts of nucleated cells and the percentage of each type were determined. HE staining and PAS staining was employed for observing the lung pathological changes. The percentages of Th17 cells and regulatory T cells (Treg) in the lung issue were determined by flow cytometry. The level of interleukin-17 (IL-17) in BALF was measured using ELISA. Results Compared with the NA group, the total number of nucleated cells, the percentage of neutrophils and the percentage of eosinophils in BALF in the NAAG group were obviously reduced; lung tissue pathologic changes were improved in the NAAG group; goblet cell hyperplasia and the level of IL-17 in BALF in the NAAG group were significantly down-regulated; the proportion of Treg in the lung increased and the proportion of Th17 cells in the lung decreased in the NAAG group. Conclusion After NA mice are treated with AG490 during the sensitization phase, the proportion of Treg in the lung would increase and the proportion of Th17 cells in the lung would decrease. AG490 could attenuate the airway inflammation in the mouse model of NA.
PMID: 27371836 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
CBS Local |
'Wing' Asthma Prevention Invention Gets FDA Clearance
CBS Local “Asthma doesn't have to be reactive,” Brimer said. Want one? Cohen says they're gearing up to launch a beta edition of the 'Wing' to the public this fall. Sparo Labs has raised $2.2 million, including a $450,000 investment announced this week by the … Sparo gets FDA clearance for asthma-related device Sparo Labs gets FDA clearance for OTC device to help asthma patients track lung function St. Louis startup gets FDA approval for asthma-control device |
View full post on asthma – Google News